Skip to main content
SpringerLink
Log in

Hadrontherapy in the context of cancer care in Italy

  • Original Paper
  • Published:
Health and Technology Aims and scope Submit manuscript

Abstract

Purpose

The present article aims to illustrate the development of hadrontherapy in Italy in a narrative description.

Methods

A review of historical documents and a search of relevant scientific literature articles was performed by internet, pubmed and web of science.

Results

The hadrontherapy projects started in Italy in the 90th and allowed the realization of centres equipped by cyclotron or synchrotron able to deliver proton and carbon ion radiotherapy. The clinical results worldwide confirmed the effectiveness of this treatment modality and the inclusion in the essential levels of assistance (LEA) with reimbursement by the Italian health public system. The “Associazione Italiana di Radioterapia e Oncologia Clinica (AIRO)” supported from the beginning the introduction of hadrontherapy and promoted its use in the clinical setting. Four centres are currently under operation allowing the Italian patients to receive this innovative treatment modality.

Conclusions

Nowadays, hadrontherapy has gained a relevant consideration in the scientific community and is recognized as an advanced technique that should be recommended in specific clinical settings. The technological development allows the installation of new machines and could lead to a larger diffusion in the next future thanks to the smaller sized and less costly installations in cancer centres and in the hospitals with relevant oncological activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Availability of data and material (data transparency):

Not applicable since it is a review article.

Code availability (software application or custom code):

Not applicable since it is a review article.

References

  1. AIOM. I numeri del cancro in Italia 2023. Intermedia Ed.; 2022.

  2. Piano Oncologico Nazionale. documento di pianificazione e indirizzo per la prevenzione e il contrasto del cancro 2023–2027. website: https://www.salute.gov.it/imgs/C_17_pubblicazioni_3292_allegato.pdf.

  3. Borras JM, Lievens Y, Barton M, Corral J, Ferlay J, Bray F, Grau C. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiother Oncol. 2016;119:5–11. https://doi.org/10.1016/j.radonc.2016.02.016

    Article  Google Scholar 

  4. De Lorenzo F. 15° Rapporto sulla condizione assistenziale dei malati oncologici. Roma 18–21 maggio 2023 XVIII Giornata nazionale del malato oncologico, FAVO. 2022.

  5. Amaldi U, Tosi G. Per Un Centro Di Teleterapia con Adroni. Fondazione TERA; 1991.

  6. Amaldi U, Silari M. In: Amaldi U, Silari M, editors. The TERA Project and the Centre for Oncological Hadrontherapy. INFN-LNF Frascati (Roma) Italy; 1994.

  7. Amaldi U, Grandolfo M, Picardi L. In: Amaldi U, Grandolfo M, Picardi L, editors. The RITA Network and the design of compact proton accelerators. INFN-LNF Frascati (Roma) Italy; 1996.

  8. Amaldi U. In: Amaldi U, editor. The National Centre for Oncological Hadrontherapy at Mirasole. INFN-LNF Frascati (Roma) Italy; 1997.

  9. Amaldi U, Magrin G. In: Amaldi U, Magrin G, editors. The path to the Italian National Centre for Ion Therapy. INFN-LNF Frascati (Roma) Italy; 2005.

  10. Particle Therapy Co-Operative Group. (PTCOG) website. https://www.ptcog.site/

  11. Orecchia R, Srivastava A, Fiore MR, Vitolo V, Fossati P, Vischioni B, Iannalfi A, Tuan J, Ciocca M, Molinelli S, Mirandola A, Vilches G, Mairani A, Tagaste B, Baroni G, Rossi S, Krengli M. Proton Beam radiotherapy: report of the first patient treated at the Centro Nazionale Di Adroterapia Oncologica (CNAO). Tumori. 2013;99:e34–7. https://doi.org/10.1007/s11547-013-0345-0

    Article  Google Scholar 

  12. Rossi S. Hadron Therapy achievements and challenges: the CNAO experience. Physics. 2022;4:229–57. https://doi.org/10.3390/physics4010017

    Article  Google Scholar 

  13. Orlandi E, Barcellini A, Vischioni B, Fiore MR, Vitolo V, Iannalfi A, Bonora M, Chalaszczyk A, Ingargiola R, Riva G, Ronchi S, Valvo F, Fossati P, Ciocca M, Mirandola A, Molinelli S, Pella A, Baroni G, Pullia MG, Facoetti A, Orecchia R, Licitra L, Vago G, Rossi S. The role of Carbon Ion Therapy in the changing Oncology Landscape-A Narrative Review of the literature and the Decade of Carbon Ion experience at the Italian National Center for Oncological Hadrontherapy. Cancers (Basel). 2023;15:5068. https://doi.org/10.3390/cancers15205068

    Article  Google Scholar 

  14. Orecchia R, Krengli M, Amichetti M, Benassi M, Biti G, Magnani V, Magrini S, Rossi S, Santoni R. Gruppo di studio sulla radioterapia con adroni. Implementazione di una rete di centri clinici sul territorio nazionale italiano. Omicron Ed. Genova - omicred@tin.it - www.omicred.com. Il Radiologo. 2004; Suppl. 3/2004.

  15. Ahern V. Selecting patients for proton beam therapy. J Med Radiat Sci. 2021;68:2–3. https://doi.org/10.1002/jmrs.454. Epub 2020 Dec 12021.

    Article  Google Scholar 

  16. Burnet NG, Mee T, Gaito S, Kirkby NF, Aitkenhead AH, Anandadas CN, Aznar MC, Barraclough LH, Borst G, Charlwood FC, Clarke M, Colaco RJ, Crellin AM, Defourney NN, Hague CJ, Harris M, Henthorn NT, Hopkins KI, Hwang E, Ingram SP, Kirkby KJ, Lee LW, Lines D, Lingard Z, Lowe M, Mackay RI, McBain CA, Merchant MJ, Noble DJ, Pan S, Price JM, Radhakrishna G, Reboredo-Gil D, Salem A, Sashidharan S, Sitch P, Smith E, Smith EA, Taylor MJ, Thomson DJ, Thorp NJ, Underwood TS, Warmenhoven JW, Wylie JP, Whitfield G. Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapy. Br J Radiol. 2022;95:20211175. https://doi.org/10.1259/bjr.20211175

    Article  Google Scholar 

  17. Malouff TD, Vallow LA, Seneviratne D, Mahajan A, Foote RL, Hoppe B, Beltran C, Buskirk SJ, Krishnan S, Trifiletti DM. Estimating the Number of Patients Eligible for Carbon Ion Radiotherapy in the United States. Int J Part Ther. 2020;7:31–41. https://doi.org/10.14338/IJPT-19-00079.1

    Article  Google Scholar 

  18. D.P.C.M 12 gennaio 2017 Definizione e aggiornamento dei livelli essenziali di assistenza (LEA), di cui all’articolo 1, comma 7, del decreto legislativo 30 dicembre 1992, n. 502, G.U. n. 65, 18 marzo 2017. https://temi.camera.it/leg18/temi/tl18_aggiornamento_dei_livelli_essenziali_di_assistenza__lea_.html

  19. Tambas M, van der Laan HP, Steenbakkers RJHM, Doyen J, Timmermann B, Orlandi E, Hoyer M, Haustermans K, Georg P, Burnet NG, Gregoire V, Calugaru V, Troost EGC, Hoebers F, Calvo FA, Widder J, Eberle F, van Vulpen M, Maingon P, Skóra T, Weber DC, Bergfeldt K, Kubes J, Langendijk JA. Current practice in proton therapy delivery in adult cancer patients across Europe. Radiother Oncol. 2022;167:7–13. https://doi.org/10.1016/j.radonc.2021.12.004

    Article  Google Scholar 

  20. ASTRO model policies. Proton Beam Therapy 2017. https://www.astro.org/uploadedFiles/_MAIN_SITE/Daily_Practice/Reimbursement/Model_Policies/Content_Pieces/ASTROPBTModelPolicy.pdf

  21. Mishra MV, Aggarwal S, Bentzen SM, Knight N, Mehta MP, Regine WF. Establishing evidence-based indications for proton therapy: an overview of current clinical trials. Int J Radiat Oncol Biol Phys. 2017;97:228–35. https://doi.org/10.1016/j.ijrobp.2016.10.045

    Article  Google Scholar 

  22. Langendijk JA, Hoebers FJP, de Jong MA, Doornaert P, Terhaard CHJ, Steenbakkers RJHM, Hamming-Vrieze O, van de Kamer JB, Verbakel WFAR, Keskin-Cambay F, Reitsma JB, van der Schaaf A, Boersma LJ, Schuit E. National Protocol for Model-based selection for Proton Therapy in Head and Neck Cancer. Int J Part Ther. 2021;8:354–65. https://doi.org/10.14338/IJPT-20-00089

    Article  Google Scholar 

  23. Troeller A, Yan D, Marina O, Schulze D, Alber M, Parodi K, Belka C, Söhn M. Comparison and limitations of DVH-based NTCP models derived from 3D-CRT and IMRT data for prediction of gastrointestinal toxicities in prostate cancer patients by using propensity score matched pair analysis. Int J Radiat Oncol Biol Phys. 2015;91:435–43. https://doi.org/10.1016/j.ijrobp.2014.09.046

    Article  Google Scholar 

  24. Mee T, Kirkby NF, Kirkby KJ. Mathematical Modelling for Patient Selection in Proton Therapy. Clin Oncol (R Coll Radiol). 2018;30:299–306. https://doi.org/10.1016/j.clon.2018.01.007

    Article  Google Scholar 

  25. Loap P, De Marzi L, Mirandola A, Dendale R, Iannalfi A, Vitolo V, Barcellini A, Filippi AR, Jereczek-Fossa BA, Kirova Y, Orlandi E. Development and implementation of Proton Therapy for Hodgkin Lymphoma: challenges and perspectives. Cancers. 2021;13(15):3744. https://doi.org/10.3390/cancers13153744

    Article  Google Scholar 

  26. Brodin NP, Kabarriti R, Pankuch M, Schechter CB, Gondi V, Kalnicki S, Guha C, Garg MK, Tomé WA. A quantitative clinical decision-support strategy identifying which patients with Oropharyngeal Head and Neck Cancer May Benefit the most from Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019;104:540–52. https://doi.org/10.1016/j.ijrobp.2018.11.039

    Article  Google Scholar 

  27. Aldenhoven L, Ramaekers B, Degens J, Oberije C, van Loon J, Dingemans AC, De Ruysscher D, Joore M. Cost-effectiveness of proton radiotherapy versus photon radiotherapy for non-small cell lung cancer patients: exploring the model-based approach. Radiother Oncol. 2023;183:109417. https://doi.org/10.1016/j.radonc.2022.11.006

    Article  Google Scholar 

  28. ClinicalTrials.com, https://clinicaltrials.gov/.

  29. Youssef I, Yoon J, Mohamed N, Zakeri K, Press RH, Chen L, Gelblum DY, McBride SM, Tsai CJ, Riaz N, Yu Y, Cohen MA, Dunn LA, Ho AL, Wong RJ, Michel LS, Boyle O, Singh J, Kriplani B, Ganly A, Sherman I, Pfister EJ, Fetten DJ, Lee J. Toxicity profiles and survival outcomes among patients with nonmetastatic Oropharyngeal Carcinoma treated with intensity-modulated Proton Therapy vs intensity-modulated Radiation Therapy. Jama Netw. 2022;5:e2241538. https://doi.org/10.1001/jamanetworkopen.2022.41538

    Article  Google Scholar 

  30. Stacchiotti S, Sommer J, Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015;16:e71–83. https://doi.org/10.1016/S1470-2045(14)71190-8

    Article  Google Scholar 

  31. Dong M, Liu R, Zhang Q, Luo H, Wang D, Wang Y, Chen J, Ou Y, Wang X. Efficacy and safety of carbon ion radiotherapy for bone sarcomas: a systematic review and meta-analysis. Radiat Oncol. 2022;17(1):172. https://doi.org/10.1186/s13014-022-02089-0

    Article  Google Scholar 

  32. Huang Q, Hu J, Chen L, Lin W, Yang J, Hu W, Gao J, Zhang H, Lu JJ, Kong L. Carbon ion radiotherapy combined with immunotherapy: synergistic anti-tumor efficacy and preliminary investigation of ferroptosis. Cancer Immunol Immunother. 2023;72:4077–88. https://doi.org/10.1007/s00262-023-03544-x

    Article  Google Scholar 

  33. Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O’Reilly MS, Gay CM, Altan M, Lu C, Cascone T, Koutroumpakis E, Sheshadri A, Zhang X, Liao L, Zhu XR, Heymach JV, Nguyen QN, Liao Z. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol. 2024;193:110121. https://doi.org/10.1016/j.radonc.2024.110121

    Article  Google Scholar 

  34. Hu J, Huang Q, Hu W, Gao J, Yang J, Zhang H, Lu JJ, Kong L. A protocol for a randomized trial evaluating the role of carbon-ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma. Cancer Med. 2024 Jan 11. https://doi.org/10.1002/cam4.6742. Online ahead of print.

  35. Sener U, Webb M, Breen WG, Neth BJ, Laack NN, Routman D, Brown PD, Mahajan A, Frechette K, Dudek AZ, Markovic SN, Block MS, McWilliams RR, Dimou A, Kottschade LA, Montane HN, Kizilbash SH, Campian JL. Proton Craniospinal Irradiation with Immunotherapy in two patients with Leptomeningeal Disease from Melanoma. J Immunother Precis Oncol. 2024;7:1–6. https://doi.org/10.36401/JIPO-23-20

    Article  Google Scholar 

Download references

Funding

No funding support.

Author information

Authors and Affiliations

  1. DISCOG, University of Padua, Padua, Italy

    Marco Krengli

  2. Unity of Radiotherapy, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy

    Marco Krengli

  3. Department of Biomedical and Dental Sciences, and Morphological, and Functional Images, University of Messina, Messina, Italy

    Stefano Pergolizzi

  4. Unity of Radiotherapy AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy

    Cinzia Iotti

Authors
  1. Marco Krengli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Pergolizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cinzia Iotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MK and CI equally contributed to article conception; MK drafted the article; all authors (MK, SP and CI) reviewed and approved the article.

Additional declarations for articles in life science journals that report the results of studies involving humans and/or animals.

Corresponding author

Correspondence to Marco Krengli.

Ethics declarations

Ethics approval (include appropriate approvals or waivers):

Not applicable since it is a review article.

Consent for publication (include appropriate statements):

Not applicable since it is a review article.

Consent to participate (include appropriate statements):

Not applicable since it is a review article.

Conflicts of interest/Competing interests (include appropriate disclosures):

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krengli, M., Pergolizzi, S. & Iotti, C. Hadrontherapy in the context of cancer care in Italy. Health Technol. (2024). https://doi.org/10.1007/s12553-024-00846-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12553-024-00846-7

Keywords

Search

Navigation